PNC-27
FDA APPROVAL PENDING
Preclinical
Longevity
PNC-27
0
Amino acids
Molecular weight
Peptide
Type
PNC-27 is a synthetic 32-residue chimeric peptide combining a p53-derived HDM-2 binding domain with a penetratin cell-penetrating leader sequence. It selectively targets cancer cells by binding to membrane-associated HDM-2 (MDM2), inducing transmembrane pore formation and necrotic cell lysis while sparing normal cells. It is studied in preclinical research for a range of malignancies including breast cancer, melanoma, leukemia, pancreatic, ovarian, and cervical cancers.
Top researched benefits
Overview of PNC-27
PNC-27 binds to HDM-2 (MDM2) expressed on the plasma membrane of cancer cells — an expression pattern absent in normal cells — triggering the formation of transmembrane pores that cause leakage of cellular contents and necrotic tumor cell death. The penetratin sequence enables membrane interaction while the p53 residues 12–26 domain confers selective HDM-2 binding.
cancer research
- PNC-27 shows selective cytotoxicity against pancreatic cancer cells in research.
- Demonstrated effectiveness against breast cancer cell lines.
- Induces necrosis of K-562 leukemia cells through HDM-2 binding.
- Shows selective targeting of melanoma cells.
mechanism studies
- Most effective against cancers with high membrane HDM-2 expression.
- Model compound for studying cancer-selective therapies.
Typical Dose
1–2mg per injection
Frequency
once daily
Cycle Duration
2–4 weeks per research protocol
Storage
Lyophilized: store at -20°C, stable at room temperature for up to 3 weeks. Reconstituted: store at 2–8°C for up to 14 days; for long-term, store at -18°C or below with carrier protein (0.1% HSA/BSA); avoid freeze-thaw cycles.
No visual available
Due to this peptide having no amino acids, there is no molecular chain to display.
Chemical Makeup
Key benefits
Selectively induces necrotic lysis of cancer cells expressing membrane-associated HDM-2, with no observed cytotoxicity to normal untransformed cells in preclinical models
Demonstrated in vitro and ex vivo efficacy against a broad spectrum of cancers including breast cancer, melanoma, pancreatic cancer, leukemia, ovarian cancer, and cervical cancer
Kills poorly differentiated non-solid tumor leukemia cells through HDM-2 membrane expression-dependent pore formation, offering a potential mechanism against hematological malignancies
In vivo animal model studies have shown tumor eradication with no reported off-target effects on healthy tissue
Community interest
This peptide is still gaining traction in the community.
p53-HDM2 Chimeric Peptide | Selective Anticancer Agent
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoPNC-27 Molecular Information
View the scientifc details of PNC-27.
Molecular Weight
4031.73DaChain Length
0Amino AcidsType
PeptidePNC-27 Protocols
Subcutaneous injection is the sole documented delivery route for PNC-27, a lyophilized anticancer peptide (MW 4031.7 g/mol) that must be reconstituted with bacteriostatic water prior to use. Abdominal injection is the preferred site; morning administration at a consistent time is recommended to facilitate daily monitoring.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Establish baseline tolerability and assess for injection-site reactions before dose escalation | 100 | 1 day range | SubQ |
| Gradually increase dose to allow physiological adaptation while monitoring for systemic effects during weeks 3–4 of a titration cycle | 200 | 1 day range | SubQ |
| Reduce cumulative daily exposure while maintaining consistent HDM-2 binding stimulus across the week for preclinical efficacy assessment | 250 | 3 week range | SubQ |
| Sustain therapeutic exposure at the target dose range for ongoing preclinical cancer cell research during weeks 5–8 of a cycle | 300 | 1 day range | SubQ |
| Maximize HDM-2-mediated membrane pore formation and cancer cell lysis at the upper end of the preclinical dose range | 500 | 1 day range | SubQ |
| Complete an 8–16 week titration cycle escalating from 100 mcg to 500 mcg daily to map dose-response across the full research range | 400 | 5 week range | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Allow the PNC-27 lyophilized powder vial to reach room temperature before opening
- Draw 3.0 mL of bacteriostatic water into a sterile syringe (yields 10 mg/mL for a 30 mg vial)
- Inject the bacteriostatic water slowly down the inner wall of the vial — never directly onto the powder
- Gently swirl or roll the vial between your palms until the powder is fully dissolved — do not shake
- Label the vial with the reconstitution date and concentration
- Refrigerate the reconstituted solution at 2–8°C protected from light; use within 2–7 days or freeze below -18°C for longer storage
- Draw the calculated dose volume into an insulin syringe before each injection (at 10 mg/mL, 1 unit on a U-100 syringe = 100 mcg)
- Clean the injection site with an alcohol swab and allow it to dry completely before injecting
- Pinch the skin at the injection site and insert the needle at a 45–90 degree angle (45° if lean, 90° if more subcutaneous tissue present)
- Inject slowly and steadily, then wait 5 seconds before withdrawing the needle
- Apply gentle pressure to the site — do not rub
- Rotate injection sites each dose across the abdomen, thighs, and upper arms to reduce local irritation
PNC-27 Cycle
The PNC-27 Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 0-0
- Binding to membrane HDM-2 begins
- Week 0-0
- Pore formation and cancer cell necrosis
- Week 0-0
- Tumor reduction in animal models
- Week 0-0
- Human clinical trials not yet conducted
Dosing tools
PNC-27 Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
PNC-27
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg PNC-27 vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- PNC-27
- Dosing
- 1–2mg per injection
- Dosing Frequency
- once daily
- Cycle Duration
- 2–4 weeks per research protocol
- Storage
- Lyophilized: store at -20°C, stable at room temperature for up to 3 weeks. Reconstituted: store at 2–8°C for up to 14 days; for long-term, store at -18°C or below with carrier protein (0.1% HSA/BSA); avoid freeze-thaw cycles.
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Side effects
Contraindications
Not approved for human use
Experimental research peptide only
Cancers without membrane HDM-2 may not respond
Stop signs
Not applicable - not approved for human use
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
PNC-27Research References
PNC-27 is a preclinical compound
PNC-27
PNC-27 is a preclinical compound
Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
PNC-27 binds membrane-bound HDM-2, inducing pore formation and cancer cell necrosis while sparing normal cells.
n.d.
Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes
PNC-27 also enters cancer cells and disrupts mitochondrial membranes.
n.d.
PNC-27 Induces Tumor Cell Necrosis of Leukemia Cells
PNC-27 induces necrosis of K-562 leukemia cells lacking p53 through p53-independent pathway.
n.d.
PNC-27, a Chimeric p53-Penetratin Peptide
PNC-27 binds HDM-2 in p53 peptide-like structure, induces selective membrane-pore formation leading to cancer cell lysis.
n.d.
Calculate peptide dosages
Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.
